Showing results (171-180 of 261) with videos related to
Sort By:
Pageof 27
Blood|June 15, 2023
Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphomaPhilippe Armand, Pier Luigi Zinzani, Hun Ju Lee, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2018
Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 TrialPhilippe Armand, Andreas Engert, Anas Younes, et al.The New England Journal of Medicine|December 2, 2011
Interleukin-2 and regulatory T cells in graft-versus-host diseaseJohn Koreth, Ken-ichi Matsuoka, Haesook T Kim, et al.Leukemia|November 7, 2021
A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemiaDeepti Gadi, Alec Griffith, Svitlana Tyekucheva, et al.Haematologica|May 7, 2013
A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphomaJennifer R Brown, Bradley Messmer, Lillian Werner, et al.Blood|February 3, 2017
PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapyTakeru Asano, Yusuke Meguri, Takanori Yoshioka, et al.Nature Medicine|August 12, 2020
A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphomaFathima Zumla Cader, Xihao Hu, Walter L Goh, et al.The Lancet. Oncology|September 17, 2021
Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 studyMatthew S Davids, Benjamin L Lampson, Svitlana Tyekucheva, et al.Blood Advances|March 26, 2026
A phase I/II Study of Duvelisib plus Venetoclax in Patients with Relapsed/Refractory CLL/SLL or Richter TransformationJennifer L Crombie, Christine E Ryan, Yue Ren, et al.Blood|January 29, 2010
Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesisJulia A Brown, Kristen Stevenson, Haesook T Kim, et al.Pageof 27